Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Work In Process (2025)

Outlook Therapeutics (OTLK) has disclosed Work In Process for 1 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Work In Process changed N/A to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a N/A change, with the full-year FY2025 number at $958539.0, changed N/A from a year prior.
  • Work In Process was $1.1 million for Q4 2025 at Outlook Therapeutics, up from $958539.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $3.7 million in Q2 2025 to a low of $271190.0 in Q1 2025.